Growth Perspectives: Key Highlights from DCAT 2024
Frost & Sullivan
APRIL 3, 2024
Growth Opportunity 2 – Medical Cannabidiol (CBD) Global regulatory shifts toward legalizing medical cannabis and CBD products highlight the growing interest in cannabis-based treatments. Partnerships with specialty CDMOs experienced in manufacturing schedule 1 products can accelerate clinical trials and R&D.
Let's personalize your content